Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
Biomaterials. 2022 Mar;282:121433. doi: 10.1016/j.biomaterials.2022.121433. Epub 2022 Feb 19.
Immunotherapy has emerged as a promising cancer treatment modality. Despite the rapid progress in cancer immunotherapy, the therapeutic efficiency and clinical translation of immunotherapy are not as satisfactory as expected, especially for the patients with immune-cold tumors. Immunogenic cell death (ICD) represents a particular form of tumor cell death accompanied by the production of tumor-specific antigens, which facilitates the infiltration of effector T cells and potentiates immune response in solid tumors. Thus, ICD contributes to stimulating immune-cold tumors to immune-hot ones. Increasing evidence shows that photodynamic therapy (PDT) is able to effectively induce ICD. Recently, a variety of photodynamic nanotherapeutics have been developed to induce ICD and to potentiate cancer immunotherapy. Herein, this review outlines the recent advances in the field at the intersection of PDT, nanotechnology and ICD, including PDT-induced ICD, PDT-based synergistic induction of ICD, and multimodal immunotherapy in basis of PDT-induced ICD. Finally, the prospects and challenges of these photodynamic nanotherapeutics in ICD induction-based cancer immunotherapy are discussed.
免疫疗法已成为一种有前途的癌症治疗方法。尽管癌症免疫疗法取得了快速进展,但免疫疗法的治疗效果和临床转化并不如预期的那样令人满意,尤其是对于免疫冷肿瘤患者。免疫原性细胞死亡 (ICD) 代表了一种特殊形式的肿瘤细胞死亡,伴随着肿瘤特异性抗原的产生,促进效应 T 细胞的浸润,并增强实体瘤中的免疫反应。因此,ICD 有助于将免疫冷肿瘤刺激为免疫热肿瘤。越来越多的证据表明,光动力疗法 (PDT) 能够有效地诱导 ICD。最近,已经开发出多种光动力纳米疗法来诱导 ICD 并增强癌症免疫疗法。本文概述了 PDT、纳米技术和 ICD 交叉领域的最新进展,包括 PDT 诱导的 ICD、基于 PDT 的 ICD 协同诱导以及基于 PDT 诱导的 ICD 的多模态免疫治疗。最后,讨论了这些基于 PDT 诱导的 ICD 的光动力纳米疗法在癌症免疫治疗中的前景和挑战。